News & Updates

Use of efgartigimod, a first-in-class investigational antibody fragment targeting the neonatal Fc receptor (FCRN), demonstrates both efficacy and safety in patients with refractory, treatment-resistant generalized myasthenia gravis (MG), as shown in a study presented at EAN 2024.

Using low-dose aspirin appears to reduce the risk of colorectal cancer (CRC) in adults, suggests a study.

Treatment with anti-CD20 monoclonal antibodies appears to be a viable option for patients with relapsing-remitting multiple sclerosis (RRMS) who have uncontrolled disease following the use of alemtuzumab therapy, suggests a study presented at EAN 2024.

A diagnosis of irritable bowel syndrome (IBS), a common functional gastrointestinal disorder, appears to contribute to a reduced risk of death, but this association weakens over time, a study has shown.